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ABSTRACT
Advances in combination medical treatment have offer new perspectives for acromegaly patients 
with persistent disease activity despite receiving the available medical monotherapies. The outcomes 
of combination medical treatment may reflect both additive and synergistic effects. This review 
focuses on combination medical treatment and its current position in acromegaly, based on clinical 
studies evaluating the efficacy and safety of combined medical treatment(s) and our own experiences 
with combination therapy. Arch Endocrinol Metab. 2019;63(6):646-52
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INTRODUCTION
A cromegaly is a rare disorder predominantly caused by a growth hormone (GH)-secreting pituitary 
adenoma, consequently resulting in elevated secretion 
of insulin-like growth factor-1 (IGF-1) (1). If untreated, 
acromegaly leads to disadvantageous metabolic changes 
and comorbidities, such as hypertension, cardiovascular 
diseases, diabetes mellitus, respiratory system dysfunction 
and in particular malignant neoplasms (2-4). There 
are multiple treatment modalities for acromegaly and 
the current consensus on the treatment goals include 
normalization of IGF-1 levels, reduction of GH levels 
below 1.0 ug/L, decrease of tumour volume, and 
improvement of clinical signs and symptoms (5,6). 
Depending on patient characteristics and tumour size 
the possibilities range from surgery, medical treatment 
or radiotherapy. Treatment of acromegaly is complex 
and most cases require a stepwise, multidisciplinary 
approach to control the disease.
Transsphenoidal surgery (TSS) remains the primary 
treatment modality in most patients with acromegaly 
(5,7,8), especially in those harbouring a microadenoma 
or intrasellar macroadenoma (9,10). Surgery is effective 
in the management of acromegaly and in experienced 
centers biochemical remission rates up to 80% can be 
achieved. However, the vast majority of patients have 
macroadenomas, often with suprasellar extension. In 
these cases, the postoperative remission rates are much 
lower (11). Therefore, in patients for whom surgery 
is contra-indicated, in whom prefer pharmacological 
treatment, or in whom postoperative remission is 
not achieved, additional treatment is needed. This 
is primarily in the form of medical treatment with 
radiotherapy generally reserved as a third-line treatment 
option (7,12). 
The medical treatment options are as follows: 
dopamine agonists (e.g., cabergoline), first-generation 
long-acting somatostatin receptor ligands (SRLs), the 
GH receptor antagonist pegvisomant (PEGV) and 
the second-generation somatostatin multi-receptor 
ligand pasireotide long-acting release (PAS-LAR). 
Despite significant medical and surgical advances, many 
acromegaly patients are not adequately controlled. 
For these patients advances in combination medical 
treatment offer new perspectives. The outcomes of 
combination medical treatment may reflect both 
additive and synergistic effects. This review aims to 
discuss the current position of combined medical 
treatment options in acromegaly. The proposed 
position of combined medical treatment in acromegaly 
presented in this review are based on clinical studies 
evaluating the efficacy and safety of combined medical 
treatment(s) and our own experiences with combination 
therapy. 
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WHAT IS THE EFFICACY OF COMBINATION 
THERAPY?
First-line medical treatment according to the recently 
published consensus criteria of Melmed and colleagues 
(6) remains first-generation SRLs monotherapy with 
lanreotide Autogel (ATG) or octreotide long-acting 
repeatable (LAR). SRLs act mainly on the somatostatin 
receptor subtype 2a (SST2a) to inhibit GH secretion and 
normalize both GH and IGF-1 levels with an efficacy rate 
of about 25%-45% (13-17). If biochemical control is not 
achieved after administering the maximal dose of first-
generation SRLs, the consensus criteria (6) recommend 
that treatment should be individualized based on 
the presence or absence of clinically relevant residual 
tumour and impaired glucose tolerance. Dopamine 
agonists monotherapy (e.g., cabergoline), which are 
acting on dopamine 2 receptors, can be considered as 
first-line medical therapy postsurgery only for patients 
with modestly elevated GH and IGF-1 levels (IGF-1 
<2.5 x upper limit of normal (ULN) (6,7,18,19). 
There are multiple options for second-line therapy as 
recommended by the consensus criteria (6): PAS-LAR 
monotherapy or PEGV combined with or substituted 
for first-generation SRLs. PEGV monotherapy has a 
reported efficacy rate up to 89% (20). Similarly, PEGV 
in combination with first-generation SRL has the ability 
to normalize IGF-1 levels in the majority of patients, 
provided that the appropriate dose has been applied. 
According to the consensus criteria, PEGV substituted 
for or combined with first-generation SRL therapy is 
recommended for patients with no significant response 
(<20% IGF-1 reduction) during first-generation SRLs 
monotherapy (6). However, we recommend that 
combination therapy with first-generation SRL and 
PEGV is the best choice as second-line option in all 
non-responders (defined as IGF-1 >1.3 x ULN) by 
using the following arguments (21): 
1. The potential advantage of combination 
therapy is that a lower PEGV dosage is needed 
to normalize IGF-1 levels compared with 
monotherapy of PEGV, leading to a reduction 
in injection frequency for patients (22-24). 
2. There are indications that combination therapy 
might have a favourable effect on quality of 
life (QoL) compared to first-generation SRLs 
monotherapy, including the ones who are 
biochemically controlled (25). 
3. Although monotherapy with PEGV does not 
reduce tumour size, combination therapy with 
first-generation SRL may result in tumour 
size control or even tumour shrinkage in most 
patients (23). 
4. Headaches may be alleviated during 
combination therapy with PEGV and first-
generation SRL. It is proposed that nociceptive 
peptides are inhibited by first-generation SRLs, 
making it the favourable treatment option for 
patients with headaches (26,27). 
Initiating combination therapy with first-generation 
SRLs and PEGV is not preferred in patients showing 
poor control of diabetes during first-generation SRLs 
monotherapy. In patients receiving first-generation 
SRLs with worsening of the glucose control, previous 
studies have shown that PEGV therapy had a more 
favourable effect on the glycaemic control (28-30). 
In those cases, PEGV monotherapy would be a more 
suitable option as it may improve glucose metabolism 
by reducing insulin resistance (28-30). This is more or 
less in accordance with the consensus criteria (6), that 
recommend patients with pre-existing clinically relevant 
impaired glucose metabolism should be switched 
from first-generation SRLs to PEGV monotherapy. In 
addition, in patients with no biochemical significant 
response (<20% IGF-1 reduction) and without 
significant tumour shrinkage (<25% tumour volume 
reduction) during first-generation SRLs monotherapy, 
PEGV monotherapy is recommended. The maintenance 
of first-generation SRLs has potentially no additional 
benefit and increased the risk of adverse events such as 
cholelitiasis.
The consensus criteria recommend the addition 
of cabergoline to continued first-generation 
SRLs treatment in a small proportion of patients 
with modestly elevated IGF-1 levels during SRL 
administration (6). This recommendation is based on a 
previous report that showed that IGF-1 normalization 
has been observed only in patients with modestly 
elevated IGF-1 levels (19). The exact mechanism 
how the combination therapy of cabergoline and 
first-generation SRL treatment imposes a synergistic 
effect on the suppression of GH is not known (31-
33). Proposed mechanism includes increased intestinal 
transit time (34), crosstalk of G-coupled receptors or 
dimerization on the cell (post-) membrane level (35) or 
paradoxical nonobligatory hetero-dimerization (36). 
Regarding the efficacy, in a meta-analysis consisting 
of 77 patients, up to 50% achieved normalized IGF-1 
levels after adding cabergoline therapy (19). 
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PEGV and cabergoline combination therapy may 
offer additional benefits to a select group of patients 
with slightly elevated IGF-1 levels during PEGV 
monotherapy. However, the use of this combination 
treatment does not appear to be exceptional in clinical 
practice, as 10% of acromegaly patients included in 
the ACROSTUDY (37) were using this combination 
therapy. A retrospective study investigated the efficacy 
of this combination therapy, and found that PEGV in 
combination with cabergoline normalized IGF-1 levels 
in 4 out of 14 acromegaly patients (28%) and decreased 
IGF-1 levels in 9 out of 14 patients (64%) (38). A 
significant response to this combination treatment 
was associated with baseline IGF-1 levels (IGF-1 <1.6 
x ULN), female gender, higher baseline prolactin 
concentrations and a lower body weight (38). A 
prospective study investigating PEGV and cabergoline 
mono- and combination therapy, showed that the 
combination of low-dose PEGV and cabergoline 
treatment resulted in 68% of patients in normalization 
of IGF-1 levels (39). Moreover, they suggest that this 
combination treatment is more effective in reducing 
IGF-1 levels than PEGV or cabergoline treatment alone 
(39). Co-administration of PEGV and cabergoline has 
several advantages over the PEGV and first-generation 
SRL combination treatment, as cabergoline is orally 
administered, less expensive than first-generation SRLs 
and overall well-tolerated. 
The current consensus criteria (6) advocate PAS-
LAR monotherapy as second-line treatment for patients 
without biochemical response to first-generation SRLs 
if a clinically relevant residual tumour that is unsuitable 
for resection is present. In accordance with the current 
consensus criteria (6), we hypothesize that in particular 
young patients (aged <40 years) with macroadenomas 
that show tumour growth during first-generation SRL 
monotherapy or PEGV [i.e., clinically aggressive tumours 
(40)], PAS-LAR monotherapy can be considered as a 
next treatment step before starting with radiotherapy 
(21). The same strategy can be applied for patients whose 
disease was previously not controlled by first-generation 
SRLs with tumour growth (i.e., reflecting the presence 
of more aggressive tumours) during PEGV monotherapy 
(21). In addition, we recommend to switch to PAS-LAR 
monotherapy as an alternative to PEGV monotherapy 
or combination therapy for patients with the following 
baseline clinical features (21): 
1. Patients whose disease was previously not 
controlled by first-generation SRLs, who 
experience side-effects, or who are intolerant to 
PEGV monotherapy. 
2. Patients with severe headaches not responsive 
to first-generation SRLs. Headaches may be 
alleviated during PAS-LAR treatment. 
There is evidence that biochemical response to 
somatostatin analogues can be predicted by the SST 
receptor subtype binding profile in the adenoma tissue 
(41,42). Whereas first-generation SRLs show a high 
preferential binding affinity for SST2a receptor and 
PAS-LAR exhibits particularly high affinity for SST5 
receptor (43). However, previous in vitro studies (44-
46) and one in vivo study (47) suggest that, overall, 
PAS-LAR exerts its anti-secretory activity mainly by 
the activation of SST2a receptor. In the latter study, 
which include patients showing a partial response to 
first-generation SRLs, the IGF-1 lowering effects of 
PAS-LAR treatment correlated with the effect of SRL 
treatment (47). Therefore, both the clinical response 
to first-generation SRL treatment and SST2a receptor 
expression on adenoma tissue could predict the 
biochemical response to PAS-LAR treatment.
The current consensus criteria (6) do not address 
the current position of PAS-LAR in combination with 
PEGV in the medical management of acromegaly since 
it was held before our data (48,49) was published. 
Preferred baseline clinical features for the use of PAS-
LAR in combination with PEGV would be patients 
without diabetes using low PEGV doses (≤80 mg/
week) during combination therapy with first-generation 
SRLs (21). The PEGV dosages can be reduced or 
sometimes even discontinued due to the PEGV sparing 
effect of PAS-LAR (48). It should be stressed that 
it is likely that those patients end up with PAS-LAR 
monotherapy. Patients biochemically controlled during 
first-generation SRL and PEGV combination therapy, 
who use first-generation SRLs every three weeks or 
have symptoms of active acromegaly in the fourth 
week after first-generation SRL administration, may 
experience symptomatic improvement after switching 
to PAS-LAR and PEGV combination therapy (21). 
At last, we postulate that PAS-LAR treatment may 
improve tumour size control or even tumour shrinkage. 
Therefore, patients experiencing tumour growth 
during first-generation SRL and PEGV combination 
therapy could be switched to PAS-LAR and PEGV 
combination therapy (21).
The safety of the different combined medical 
treatments will be addressed in the paragraph below 
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where its effect on tumour size will be discussed 
separately from other side effects.
COMBINATION THERAPY AND TUMOUR SIZE
The prevention of further tumour growth and 
consequently tumour mass complications is an 
advantageous treatment outcome in acromegaly 
patients, as the existence of large tumours is associated 
with poor clinical outcomes (50). Clinical evidence has 
shown that first-generation SRL treatment exhibits 
anti-proliferative effects and induces tumour shrinkage 
in most patients (16,51,52). Moreover, greater tumour 
shrinkage was observed in naïve patients and those 
treated with first-generation SRLs monotherapy for 
more than one year. In addition, dopamine agonists 
may exert anti-proliferative effects on pituitary tumour 
cells (53).
Detailed research on tumour shrinkage and 
combination therapy is rare. For example, in 158 patients 
the results of the biochemical efficacy of cabergoline 
and first-generation SRL combination therapy were 
available, however, information on tumour volumes is 
scarce, which could underestimate tumour shrinkage. 
However, in one study of 10 patients resistant to first-
generation SRL therapy (54), total tumour shrinkage 
went from 34 to 21 uL (p = 0.009) after the addition 
of cabergoline (0.25-2 mg/week) for a period of six 
months. For patients who are biochemically resistant 
to first-generation SRLs, the addition of cabergoline 
may be useful as SRLs could maintain long-term effects 
on tumour mass, while cabergoline may lower IGF-1 
levels.
PEGV monotherapy does not have the ability to 
decrease tumour size. In the Italian ACROSTUDY 
patients, none of the 35 patients showed significant 
tumour growth under PEGV alone, whereas in one case, 
progressive shrinkage of the adenoma was documented 
by MRI, which was no longer detectable after six years 
of treatment (55). In the same study, among the 27 
patients treated with PEGV in combination with first-
generation SRL, a significant growth of the residual 
adenoma tissue occurred in one case. However, this 
patient was characterized by clinically aggressive 
disease (40) and, when the tumour enlargement was 
noted, was eventually treated with PEGV 40 mg/day 
in combination with lanreotide ATG 120 mg/month 
(55). In the Dutch cohort among 141 patients treated 
with PEGV in combination with first-generation SRL, 
growth of the adenoma occurred in one case as well, 
while this growth was already observed before the 
addition of PEGV (23). In the report by Neggers and 
colleagues they assessed the long-term safety of the 
combined use of PEGV and first-generation SRL in a 
large group of (n = 86) patients over a longer period 
of time (56). In 14 patients the size of the tumour 
significantly decreased more than 20%, whereas tumour 
size increase was not observed (56). All in all, these 
data do suggest that PEGV does not cause significant 
increase in tumour size in acromegaly patients. 
Therefore, PEGV in combination with first-generation 
SRL should be considered as a safe approach, especially 
when first-generation SRLs still can reduce tumour size 
in PEGV treated subjects plus the fact that in a small 
number of SRL treated subjects, an increase in tumour 
size has been observed as well.
To our knowledge, there are no studies investigating 
the tumour response after long-term PAS-LAR alone 
or in combination with PEGV therapy, except for 
one. In this follow-up analysis of 47 patients from 
the PAPE study (49), which investigated patients 
who were either treated with PAS-LAR monotherapy 
or the combination of PAS-LAR and PEGV therapy, 
assessment of T1 and T2-weighted signal by MRI 
was performed. Surprisingly, the T2-weighted MRI 
signal of the adenoma was increased in 14 (30%) of 
the 47 patients during PAS-LAR treatment (57). 
The increase in T2-signal was particularly substantial 
(>50%) in eight patients, where the majority of the 
adenoma became T2-hyperintense. Generally speaking, 
a T2-hyperintense signal indicates cystic degeneration, 
tumour cell necrosis, or both, which is suggestive of 
an anti-tumour effect (57). Besides, they observed 
clinically significant (≥25%) tumour shrinkage in 5 of 
the 14 patients with adenomas in which they observed 
increased T2-signal intensity during 9 months of 
PAS-LAR treatment. Up to 30 months of PAS-LAR 
treatment, an additional decrease in tumour volume 
was observed in the adenomas of five patients (mean 
tumour volume was 2.9 cm3 at baseline, 2.3 cm3 after 
9 months of PAS-LAR, and 1.9 cm3 after about 30 
months) (58). 
Antitumour effects of somatostatin receptor ligands 
have not been reported over the last 30 years. If 
PAS-LAR could induce cystic degeneration, tumour 
cell necrosis, or both, it might affect the clinical 
management of acromegaly. Preoperative treatment 
with PAS-LAR, for example, might induce (partial) 
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cystic degeneration, tumour cell necrosis, or both, 
which could improve surgical outcomes. This potential 
antitumour effect of PAS-LAR might reduce disease 
activity and even alleviate symptoms, or detrimentally 
may induce anterior pituitary deficiencies. Therefore, 
close monitoring of pituitary tumour status is advised 
when using PAS-LAR therapy alone or in combination 
with PEGV.
SAFETY AND QUALITY OF LIFE
First-generation SRLs are generally well tolerated, 
usually with transient mild side effects. Most patients 
experience nausea, diarrhoea, gastro-intestinal related 
complaints and abdominal pain or distension. More 
severe adverse effects may include hair loss, cholelithiasis 
and bradycardia (13,16). In general, the net effect 
of first-generation SRLs on glucose metabolism is 
considered marginal. Recently, in a large meta-analysis 
of 47 prospective interventional trials, they studied in 
1,297 patients the effect of first-generation SRLs on 
glucose homeostasis (59). The authors show that first-
generation SRLs significantly reduce insulin secretion, 
and this was not (completely) counterbalanced by 
the reduction in IGF-1 and GH levels. Therefore, 
the net effect of SRLs on glucose metabolism may be 
clinically relevant, because most patients are already 
insulin resistant and have prediabetes irrespective of the 
biochemical control.
Regarding the safety aspects of PEGV monotherapy 
or in combination with first-generation SRLs, in a recent 
update of the ACROSTUDY (60), hepatobiliary-related 
side effects were found for up to 10% of 2,090 patients, 
from which 4% are considered related to treatment. 
From the total of 1,094 patients, 62% remained to have 
normal transaminase (TA) values during follow-up. 
There was a reported level of 3% increases in TAs > 3 
x ULN. A total of 89 patients entered the study with 
elevated TAs between 1-3 x ULN, from this 34% drifted 
downwards to normal TA values during follow-up with 
PEGV treatment, 46% remained within their baseline 
range and 10% had TAs > 3 x ULN. Lipodystrophy at 
the injection site of PEGV has been reported, which 
regressed in most patients after frequent rotation or 
after discontinuation of PEGV (61). In a subgroup of 
patients, the combination therapy of first-generation 
SRL and PEGV has favourable effects on QoL compared 
with first-generation SRL monotherapy, including the 
patients whose disease is biochemically controlled (25). 
Furthermore, an advantage of this combination therapy 
is that first-generation SRLs are typically effective in 
resolving headaches due to inhibition of nociceptive 
peptides, making it the preferred treatment for patients 
with headaches (26,27).
The adverse effects of the combination therapy of 
first-generation SRL and cabergoline include: nausea, 
headache, dizziness and hypotension (19). High 
cabergoline dosages used in Parkinson’s patients have 
valvulopathy as a known side effect (62). Lower dosages 
and/or short-term use of dopamine agonists have not 
been proven to induce valvulopathy in acromegaly 
patients (63). Such outcomes of long-term cabergoline 
and first-generation SRL combination therapy in 
acromegaly patients is not known.
PAS-LAR monotherapy has a negative effect on 
glucose metabolism. It suppresses insulin secretion 
and incretin response, resulting in a higher frequency 
of hyperglycaemia and diabetes (13,49). In two 
studies comparing first-generation SRL with PAS-LAR 
monotherapy, hyperglycaemia-related adverse events 
were described in 22-30% with first-generation SRLs 
and in 57%-65% of patients treated with PAS-LAR 
therapy (13,14). In the PAPE study, the frequency of 
diabetes mellitus doubled from 33% at baseline to 69% 
at 24 weeks and increased further to 77% at 48 weeks 
(48). The pathophysiology of hyperglycaemia appears 
to be due to a combination of insulin and incretin 
suppressive effects of PAS-LAR (64). However, 
the precise mechanism of how PAS-LAR causes 
hyperglycaemia is not well understood. In biochemically 
controlled patients during first-generation SRL and 
PEGV combination therapy, who are still experiencing 
symptoms of active acromegaly in the fourth week 
after administration of first-generation SRLs, could 
experience symptomatic improvement after switching 
to PAS-LAR and PEGV combination therapy. 
CONCLUSION
The desired treatment approach in acromegaly patients 
should take all the individual traits of the disease into 
consideration, such as: GH and IGF-1 levels, tumour 
size, acromegaly symptoms, comorbidities, costs, QoL 
and patient preferences. Although surgery remains the 
mainstay treatment, new medical combination therapies 
have offer new perspectives for acromegaly patients 
with persistent disease activity despite surgery and/
or medical monotherapies. And with the introduction 
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of new effective drugs, the medical therapies may be 
more suitable for certain types of patients. It is of 
importance to monitor medical therapies closely as 
it is crucial in controlling the disease. We elucidated 
that the use of combination therapies could provide 
sufficient biochemical or tumour control in patients 
uncontrolled under first-generation SRL monotherapy. 
Every medical combination therapy carries along 
benefits and drawbacks. In the end, the real challenge 
for the clinician is to decide in each individual patient 
whether one outweigh other treatment options.
Disclosure: AJvdL is a consultant for Pfizer, and has received 
speaker fees from Novartis, Ipsen, and Pfizer. SJCMMN has re-
ceived research grants and speaker fees from Ipsen, Novartis, and 
Pfizer, and consulting fees from Ipsen. ECC and SWFM have 
nothing to disclose.
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